Diego A. Díaz García, Medical Oncologist /CEO/Founder at CánCare – High Specialty in Oncology, shared a post on X:
“Updates on the treatment of EGFR-mutant NSCLC.
Third-gen TKIs are standard first-line. Combos with chemo or amivantamab extend PFS (and now OS in Mariposa ph3 trial). Resistance remains a challenge—tailored strategies are key.”
